Use of cannabinoids in the treatment of epilepsy
AssigneeGW Pharma Limited
InventorsGeoffrey Guy, Stephen Wright, Alice Mead, Charuta Joshi, Angus Wilfong
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Claims8
A method of treating treatment-resistant epilepsy comprising administering cannabidiol (CBD) to a subject, wherein the epilepsy is febrile infection related epilepsy syndrome (FIRES).
Dependencies are inferred from the claim text.